PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019)
10.1038/s41467-021-26548-6
Saved in:
Main Authors: | Thura, Min, Al-Aidaroos, Abdul Qader, Gupta, Abhishek, Chee, Cheng Ean, Lee, Soo Chin, Hui, Kam Man, Li, Jie, Guan, Yeoh Khay, Yong, Wei Peng, So, Jimmy, Chng, Wee Joo, Ng, Chin Hin, Zhou, Jianbiao, Wang, Ling Zhi, Yuen, John Shyi Peng, Ho, Henry Sun Sien, Yi, Sim Mei, Chiong, Edmund, Choo, Su Pin, Ngeow, Joanne, Ng, Matthew Chau Hsien, Chua, Clarinda, Yeo, Eugene Shen Ann, Tan, Iain Bee Huat, Sng, Joel Xuan En, Tan, Nicholas Yan Zhi, Thiery, Jean Paul, Goh, Boon Cher, Zeng, Qi |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Language: | English |
Published: |
NATURE PORTFOLIO
2021
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/208517 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
by: Thura, Min, et al.
Published: (2019) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
by: Thura M., et al.
Published: (2020) -
PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
by: Thura, Min, et al.
Published: (2022) -
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
by: Chee, Cheng E, et al.
Published: (2023) -
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice
by: Guo, Ke, et al.
Published: (2021)